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Metabolomics
Seeking a Unique Biomarker Signature
for Coronary Artery Syndromes*
Ronald W. Millard, PHD,† Paul R. Rosevear, PHD‡
Cincinnati, Ohio
In this issue of the Journal, Bodi et al. (1) report the
application of nuclear magnetic resonance (NMR) spectro-
scopic techniques to detect and characterize a predictive
cardiac-specific metabolomic (also known as metabonomic)
profile on the basis of systemic blood samples drawn from
patients experiencing acute coronary syndromes (ACS)
leading to myocardial tissue ischemia and infarction (i.e.,
acute myocardial ischemia [AMI]).
NMR spectroscopy datasets from a retrospectively se-
lected patient population with angioplasty-induced tran-
sient AMI and a prospective clinical study design with
patients with spontaneous acute chest pain are validated in
a porcine model of acute and sustained coronary artery
occlusion. The investigators use computational analysis of
metabolomic datasets as a putative metabolic biosignature
method to better inform and guide the treatment of patients
presenting with symptoms of ACS.
See page 1629
To obtain sensitive and specific datasets, we think it
important to reflect on criteria for biomarker use in improv-
ing the diagnosis of ACS leading to AMI and subsequent
tissue infarction. These criteria would include: 1) the spec-
ificity of the cardiac biomarker(s); 2) the time course of
biomarker presence in the sampling space; 3) the availability
of sensitive analytic methods; 4) the response time and cost
of the analytic procedure; 5) the influence of medications;
6) healthy and stable angina controls; and 7) estimates of
interpatient variability. Additional considerations include
the appropriateness of the animal model as well as patient
populations used to validate and correlate ACS with con-
ventional ischemia-induced cardiac biomarkers.
*Editorials published in the Journal of the American College of Cardiology reflect the
views of the authors and do not necessarily represent the views of JACC or the
American College of Cardiology.
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al. (2) and Tweeddale et al. (3), while Nicholson et al. (4)
coined “metabonomics” for the same concept in 1999.
Metabolomics (the more common term), defining the biolog-
ical response of a living system to a stimulus, involves the
identification and measurement of metabolites in biolog-
ical samples by either high-throughput mass spectroscopy
or NMR spectroscopy. In clinical applications, a subset of
metabolites associated with a particular disease is evalu-
ated to aid diagnosis, probe pathogenesis mechanisms,
and monitor treatment protocol outcomes. Early cardio-
vascular metabolomic studies used NMR spectroscopy to
probe myocardial energy metabolism with 31P resonances
n adenosine triphosphate, adenosine diphosphate, aden-
sine monophosphate, and phosphocreatine. Recently,
1H NMR spectroscopy has been used in cardiac metabo-
lomic studies, because the 1H nucleus has high sensitiv-
ity, and molecular profile data are obtained in minutes. In
the near future, it is expected that other NMR-sensitive
isotopes, such as 13C, will be used to identify and quantify key
metabolic compounds. Terms characterizing complex
metabolite analysis are evolving distinctive uses, such that
metabolomics is the systematic study of the unique
chemical fingerprints of specific cellular processes (most
frequently used for mass spectroscopic analyses), and
metabonomics is the quantitative measurement of the
dynamic multiparametric metabolic responses of living
systems to pathophysiological stimuli or genetic modifi-
cation (most frequently associated with NMR spectro-
scopic analyses). Technically, Bodi et al. (1) performed a
metabonomic study, looking at multiple metabolites as a
function of disease state.
Predictive biomarker profiling of patients with ACS at
risk for AMI leading to infarction and necrosis is a
relatively recent strategy. High-sensitivity C-reactive
protein and brain natriuretic peptide are prognostic
biomarkers reflecting cardiovascular inflammation and
heart failure, respectively. Monocyte chemoattractive
protein–1 and ischemia modified albumin may also be
used as biomarkers to rule out AMI and for ACS risk
stratification, respectively (5).
The detection of AMI once relied entirely on aberrant
biopotentials registered on electrocardiography. ST-segment
elevation correlates often, but not always (i.e., “silent” ischemia,
non–ST-segment elevation myocardial infarction), with myo-
cardial ischemia (ST-segment elevation myocardial infarction)
and tissue injury after coronary artery obstruction. Today,
biomarkers are used in combination with the electrocardio-
graphic signature for AMI detection.
The early search for biomarkers can be traced to the
mid-20th century. More than 4 decades ago, Hess et al. (6)
identified creatine kinase (CK) disorders in heart and
skeletal muscle disorders, and shortly afterward, Bing et al.
(7) described molecular changes in heart muscle after AMI.
This was followed by the pioneering biomarker study of
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May 1, 2012:1642–4 Ischemic Myocardial MetabolomicsShell et al. (8), in which the peak serum concentration of
CK, a rather large (43-kD monomer) intracellular myocar-
dial protein, at approximately 12 h after coronary artery
occlusion was positively correlated with myocardial infarct
size in a canine model. Subsequently, from the same
research group, Ahmed et al. (9) identified the CK-MB
isoenzyme as a cardiac-specific biomarker for myocardial
ischemia and infarction. However, Heyndrickx et al. (10),
lso in a canine model, measured elevated serum CK levels
ithout myocardial infarction after brief coronary artery
cclusion. During this period, Leidtke et al. (11) docu-
ented myocardial metabolic changes during coronary ar-
ery reductions in a swine model.
Today, suspected AMI is routinely evaluated by a panel
f biomarkers in peripheral blood samples: myoglobin,
ardiac troponin I and T, and CK-MB. Other biomarkers
f myocardial ischemia include myeloperoxidase and glyco-
en phosphorylase isoenzyme BB.
In the context of the present study, it is important to
onsider relevant coronary circulation features of large
nimal models often used in studies of myocardial metab-
lism, as Bodi et al. (1) have selected a porcine model as a
ontrol. Because they evaluated patient data in retrospective
nd prospective study components, this animal model is a
aluable calibrator and reveals relatively concordant metabo-
omic information after acute coronary artery ligation. Ca-
ine and porcine models are most commonly used in studies
hat examine facets of ACS and AMI and the accompany-
ng changes in cardiac metabolism. The canine model,
erhaps similar to the human heart with coronary artery
isease and adaptive collateral vessels, is recognized for its
ange of myocardial ischemic responses to coronary artery
cclusion due to the variable pre-existence of these coronary
rtery collateral vessels (12). In contrast, the porcine model,
sed here by Bodi et al. (1), lacks pre-existing collateral
essels and therefore is considered more similar to the
ealthy human heart (13).
Certainly, NMR spectroscopic capacity to detect met-
bolic markers combined with computational strategies
or analyzing complex datasets associated with acute or
hronic coronary artery syndromes is possible for the
eam assembled for the present study by Bodi et al. (1).
mportantly, the time required to obtain results is short,
aking 1H NMR metabolomic profiling for cardiovas-
cular disease a potentially useful tool in evaluating pa-
tients in the emergency department setting. Although the
major disadvantage of 1H NMR spectroscopy is its relative
nsensitivity compared with mass spectroscopy, this disad-
antage is usually outweighed by the low cost of sample
rocessing and speed of data acquisition. However, the
ikelihood of adoption of NMR spectroscopy by first
esponder and community-based hospitals across the
lobe would seem uncertain, if only on the basis of
nstrumentation cost and the technical expertise required
or the rapid analysis and interpretation of complex
etabolic datasets. However, the cost of NMR spectrom-ters continues to decrease and is expected to decrease
ore as the need to place spectrometers in hospital
ettings increases. This scenario was observed as the need
or magnetic resonance imaging spectrometers increased
s more local hospitals sought this technology. Statistical
nalysis of the data will become more automated, de-
reasing the need for highly skilled technical expertise
nsite. At the same time, the method significantly
dvances the prognostic value of the panoply of changes
n the myocardium’s internal milieu when the coronary
lood supply fails to meet tissue metabolic demand (14).
uch an integrative approach to metabolite profile anal-
sis as described here by Bodi et al. (1) offers substantial
ew opportunity for advanced biomarker patterning of
hat is often a rather challenging differential diagnosis of
atients presenting with AMI symptoms of ACS.
In conclusion, Bodi et al. (1) provide us with compelling
vidence that no single metabolite is likely to be unambig-
ously predictive of ischemia and altered myocardial metab-
lism that accompany ACS. They argue rather convincingly
hat an analysis of changes in the myocardial metabolic
rofile, using NMR spectroscopy combined with high-level
iostatistical assessment of complex datasets, can supplant
urrent best practices and thereby improve clinical decision
aking directing patient care for optimal outcomes. One
an only hope such advances will reduce the frequency of
oth false-positive and false-negative findings arising from
he use of current biomarkers.
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